MDxHealth SA (MDXH) shareholders
Close on Nov 18, 2026Market cap $719.62KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bleichroeder Holdings LLC Joint filing with Bleichroeder LP (33.20%), Andrew Gundlach (33.20%) | 31,648,563 | 33.20% | 13D (active) | Aug 11, 2026 |
| Andrew Gundlach Joint filing with Bleichroeder LP (32.04%), Bleichroeder Holdings LLC (32.04%) | 30,571,922 | 32.04% | 13D (active) amendment | Oct 13, 2026 |
| Laurence W. Lytton Joint filing with Lytton-Kambara Foundation (12.10%) | 18,558,988 | 19.50% | 13G (passive) amendment | Aug 13, 2026 |
| Exact Sciences Corporation Joint filing with Genomic Health, Inc. (12.00%) | 6,441,171 | 12.00% | 13G (passive) amendment | Jan 9, 2026 |
| Lytton Laurence W | 4,943,464 | 9.60% | 13G (passive) amendment | Jun 30, 2026 |
| MVM Partners, LLC Joint filing with Mvm V LP (9.74%) | 4,700,457 | 9.94% | 13D (active) amendment | Sep 27, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MDXH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bleichroeder LP | 7,378,333 | 14.36% | $3.03M | – | 0.54% |
| MVM Partners, LLC | 4,700,457 | 9.15% | $1.91M | – | 100.00% |
| Perkins Capital Management Inc | 1,411,891 | 2.75% | $579.72K | −64,550 | 0.44% |
| Citadel Advisors LLC | 509,674 | 0.99% | $209.27K | +450,040 | 0.00% |
| Jane Street Group, LLC | 503,219 | 0.98% | $206.62K | New | 0.00% |
| Gsa Capital Partners Llp | 481,985 | 0.94% | $198.00K | +470,893 | 0.01% |
| Renaissance Technologies LLC | 325,084 | 0.63% | $133.48K | +20,384 | 0.00% |
| Millennium Management LLC | 228,510 | 0.44% | $93.83K | −316,218 | 0.00% |
| Squarepoint Ops LLC | 200,281 | 0.39% | $82.24K | New | 0.00% |
| XTX Topco Ltd | 195,039 | 0.38% | $80.08K | +157,324 | 0.00% |
| Hrt Financial LP | 184,477 | 0.36% | $75.00K | +173,154 | 0.00% |
| BlackRock, Inc. | 147,063 | 0.29% | $60.38K | +42,742 | 0.00% |
| Virtu Financial LLC | 134,178 | 0.26% | $55.00K | New | 0.00% |
| Ground Swell Capital, LLC | 88,114 | 0.17% | $36.18K | New | 0.04% |
| Tower Research Capital LLC (TRC) | 36,549 | 0.07% | $15.01K | New | 0.00% |
| FAS Wealth Partners, Inc. | 22,625 | 0.04% | $9.29K | – | 0.00% |
| Lido Advisors, LLC | 20,253 | 0.04% | $8.32K | +9,756 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 20,000 | 0.04% | $8.00K | +10,000 | 0.00% |
| Intesa Sanpaolo Wealth Management | 10,000 | 0.02% | $4.11K | – | 0.00% |
| Morgan Stanley | 764 | 0.00% | $313 | −15,620 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 26 | 17M | 32.3% | 5 / 8 | 5 / 30 | 2M | 10M |
| Q1 2026 | 51 | 25M | 48.2% | 9 / 12 | 17 / 14 | 2M | 1M |
| Q4 2025 | 56 | 24M | 47.4% | 19 / 18 | 9 / 3 | 2M | 0M |
| Q3 2025 | 42 | 23M | 44.4% | 23 / 8 | 4 / 2 | 2M | 0M |
| Q2 2025 | 21 | 22M | 41.9% | 3 / 3 | 4 / 2 | 1M | 0M |
| Q1 2025 | 21 | 21M | 41.3% | 1 / 4 | 8 / 4 | 1M | 2M |
| Q4 2024 | 24 | 22M | 43.8% | 8 / 7 | 5 / 6 | 2M | 3M |
| Q3 2024 | 22 | 23M | 44.4% | 13 / 5 | 0 / 0 | 14M | 0M |
| Q2 2024 | 9 | 9M | 17.4% | 0 / 2 | 2 / 4 | 0M | 0M |
| Q1 2024 | 13 | 9M | 18.2% | 3 / 2 | 3 / 2 | 0M | 0M |
| Q4 2023 | 12 | 10M | 18.7% | 3 / 6 | 1 / 2 | 3M | 0M |
| Q3 2023 | 11 | 7M | 13.2% | 0 / 3 | 4 / 7 | 0M | 1M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael McGarrity | Chief Executive Officer, Director | 95,000 | 0.18% | Jun 3, 2026 |
| Joseph Sollee | See Remarks | – | – | Jun 3, 2026 |
| John Bellano | Chief Commercial Officer | – | – | Jun 3, 2026 |
| Brendan OConnell | VP, Finance and Accounting | – | – | Jun 3, 2026 |
| Ron Kalfus | Chief Financial Officer | – | – | Apr 13, 2026 |
| Eric Bednarski | Director | 6,903,100 | 13.44% | Aug 17, 2026 |
| MVM Partners, LLC | Director | 4,700,457 | 9.15% | Aug 17, 2026 |
| Koen Hoffman | Director | – | – | Jun 3, 2026 |
| Don M. Hardison | Director | – | – | Jun 3, 2026 |
| Sanford Jay Siegel | Director | – | – | Jun 3, 2026 |
| Hilde Windels | Director | – | – | Jun 3, 2026 |
| Michael Holder | Director | – | – | Jun 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eric Bednarski Director | Aug 13, 2026 | Buy | +2,202,643 | $0.45 | $991.19K | 6,903,100 |
| MVM Partners, LLC 10% owner | Feb 3, 2023 | Buy | +1,000,000 | $4.00 | $4.00M | 45,504,584 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MDxHealth's stock actually held short. Settlement fails (shares not delivered on time) peaked at 31,741 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Bleichroeder LP 10% Stockholder | Sep 17, 2026 | 1,500,000 | $1.06M | Sep 17, 2026 | Registered Public Offering |
See a number that looks wrong?